In contrast to RSG, INT131 did not aggravate hepatic steatosis or affect hepatic adipogenic gene expression, although it did generate equivalent or more potent PPARγ activation and regulation of downstream target genes in adipose tissues and skeletal muscle. This evidence concerns the gene PPARG and fatty liver disease.